Abstract Library

#3067 Somatostatin Analogs in Real‐World Practice for Patients with Metastatic Neuroendocrine Tumors: A Single Institution Experience in the Ouest of Algeria (CHU Oran)

Introduction: The efficacy of somatostatin analogs (SSAs) were clearly established trough pivotal trials as first‐line agents for neuroendocrine tumors (NETs), but their use in clinical practice is largely unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ameziane N, Behourah Z, Aida M, Ahed Messaoud M, Bousahba A,

Keywords: GEP-NET, Somatostatin analogs, anti proliferative action, anti secretory action, Management real world practice,

#3041 Resource Use in Patients with Carcinoid Syndrome: A Retrospective Analysis Using the French Health Insurance National (SNDS) Database

Introduction: About 20% of patients (pts) with neuroendocrine tumors (NET) suffer from carcinoid syndrome (CS), mainly from ileum and lung NET. Pts with CS experience symptoms such as diarrhea, flushes and cardiac complications. The diarrhea occurs in almost all pts with CS and can be truly debilitating. Therefore, on top of the tumor, the burden of the symptoms further impairs quality of life and is associated with additional costs related to symptom management and pts follow-up.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Walter T

Authors: Walter T, Lapeyre Mestre M, Gueguen D, Bouille C, Laborey M,

Keywords: Carcinoid syndrome, resources, health economics,

#2969 Lanreotide Autogel and Octreotide LAR Treatment Patterns: Results from a Nationwide French Retrospective Study

Introduction: Lanreotide autogel (LAN) and octreotide LAR (OCT) are long acting somatostatin analogues (LA-SSAs) used to treat acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Previous studies conducted in North America and Sweden showed some differences between both LA-SSAs in terms of dose and persistence.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Fagnani F, Feuilly M, Marteau F, de Zélicourt M, Kamenicky P,

Keywords: somatostatin analogues, treatment patterns, resource use,

#538 Cost-Utility of Sunitinib (SU) for Treatment of Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in Scotland and Wales

Introduction: SU is an oral multitargeted tyrosine kinase inhibitor approved in Europe for advanced/metastatic well-differentiated pNET.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Johns A, Eatock M, Johal S,

Keywords: Sunitinib, overall survival, cost-utility, pancreatic NET,

#514 Cost-Effectiveness of Sunitinib in Patients (Pts) with Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in the Netherlands

Introduction: Sunitinib (SU) is an oral multitargeted tyrosine kinase inhibitor approved and reimbursed in the Netherlands for use in advanced/metastatic well-differentiated pNET.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kansal A, Chao R, Patyna S, Scheijbeler H, Klok R,

Keywords: pancreatic NET, Sunitinib, overall survival, cost-effectiveness,